Drugs / TGRX-814
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06206174 | Mar 2024 → Feb 2025 overdue | acute myeloid leukemia, adult acute lymphoblastic leukemia, myelodysplastic syndrome | Shenzhen TargetRx Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGRX-814 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06206174 ↗ |
| Route | Oral | “oral, once daily administration” NCT06206174 ↗ |